# Novartis Acquires Avidity Biosciences for $12 Billion

> ma · REPORTED · 2025-11-01

Novartis acquired Avidity Biosciences for approximately $12 billion, gaining access to Avidity's proprietary Antibody Oligonucleotide Conjugate platform designed to deliver RNA-based treatments into skeletal and cardiac muscle, along with a late-stage pipeline of neuromuscular disease drug candidates. The deal was one of the largest biotech acquisitions of 2025.

About Novartis: Avidity Biosciences was a clinical-stage biotech developing Antibody Oligonucleotide Conjugate therapies designed to deliver RNA therapeutics into muscle tissue for neuromuscular diseases including myotonic dystrophy and facioscapulohumeral muscular dystrophy.

- Company: Novartis
- Sector: therapeutics
- Primary source: https://www.pharmaceutical-technology.com/features/biopharmas-2025-ma-boom-dealmaking-surges-as-patent-pressures-intensify/

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.